Clinical Trial: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Cervical Cancer
Study Type: INTERVENTIONAL
Official Title: Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Brief Summary:
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Read more